Global Autoimmune Disease Therapeutics Market Set to Reach $254.6 Billion by 2034
News related to:Autoimmune Disease Therapeutics Market · 2 min read
Dublin, Sept. 17, 2026 /CourierPR/ -- The global market for autoimmune disease therapeutics is poised for significant growth, reaching an estimated value of $254.6 billion by 2034, according to a new report. This expansion is driven by the rising prevalence and diagnosis of autoimmune disorders, the increasing use of biologics and targeted oral therapies, the broader availability of biosimilars, and sustained pharmaceutical investment in immunology research.
Biologics currently dominate the market, accounting for 66% of global revenue in 2025. Tumor necrosis factor (TNF) inhibitors represent the largest drug class, with a 29% market share. Subcutaneous products, which are easier for patients to self-administer, captured 54% of the market in 2025. Rheumatoid arthritis remains the leading disease segment, accounting for 34% of global revenue in 2025.
North America held the largest regional share at 44% in 2025, supported by advanced clinical research infrastructure, strong specialist networks, and a significant concentration of global immunology manufacturers. However, Asia-Pacific is forecast to be the fastest-growing regional market, driven by rising diagnosis rates, healthcare infrastructure investment, wider insurance coverage, and increasing biologic adoption.
Key players in the market include AbbVie, Johnson & Johnson, Pfizer, Novartis, Roche, Amgen, Eli Lilly and Company, Bristol Myers Squibb, UCB, Sanofi, GSK, Biogen, and Takeda. These companies are competing through portfolio breadth, clinical differentiation, indication expansion, licensing agreements, acquisitions, patient-support programs, and advanced delivery technology.
Recent developments include AbbVie's increased revenue outlook for its Skyrizi and Rinvoq products, and Roche's submission of a supplemental Biologics License Application for Gazyva in systemic lupus erythematosus. These moves are expected to strengthen the companies' positions in the rapidly evolving market.
The market is also seeing a shift towards mechanism-specific biologics, oral small molecules, and emerging cell- and gene-based therapies. Pipeline development is increasingly focused on B-cell depletion, CAR-T cell therapy, precision immunology, and other advanced treatment platforms for refractory systemic lupus erythematosus, multiple sclerosis, and related conditions.
However, high treatment costs, reimbursement restrictions, variable patient response, regulatory complexity, and safety concerns associated with certain drug classes may moderate market expansion. Diagnostic delays also remain a barrier, particularly for complex systemic conditions.
Despite these challenges, the convergence of increasing disease prevalence, biologic innovation, targeted oral therapy adoption, biosimilar penetration, and advanced cell-based research is expected to sustain robust growth through 2034. The market is segmented by drug modality, drug class, route of administration, disease type, end user, and geography, with primary end users including hospitals and specialty clinics.
The report highlights that the autoimmune disease therapeutics market is moderately concentrated, with major participants competing through portfolio breadth, clinical differentiation, indication expansion, licensing agreements, acquisitions, patient-support programs, and advanced delivery technology.